Advertisements
Amgen, a leading biotechnology company, is collaborating with NVIDIA to leverage generative AI for drug research and development. Amgen will utilize the NVIDIA DGX SuperPOD at its deCODE genetics’ headquarters in Reykjavik, Iceland, to build a human diversity atlas for drug target and biomarker discovery.
This strategic partnership aims to accelerate research, enhance diagnostic capabilities, and potentially pave the way for individualized therapies, reaffirming the transformative potential of advanced AI in the field of medicine.
What you should know
- Amgen plans to deploy the NVIDIA DGX SuperPOD, named Freyja, for analyzing one of the world’s largest human datasets, facilitating faster drug discovery.
- Freyja will contribute to building a human diversity atlas, facilitating the identification of disease-specific biomarkers and enabling the development of AI-driven precision medicine models. This process of identifying biomarkers enhances our understanding of how diseases manifest, empowering Freyja to assist in developing advanced computer models powered by artificial intelligence. These models are crafted to customize medical treatments based on individual differences, providing a more precise and personalized approach to medicine. Essentially, it marks a significant stride toward tailoring healthcare to each person’s unique characteristics, enhancing both diagnosis and treatment.
- The powerful system, featuring 31 NVIDIA DGX H100 nodes, aims to accelerate research by training state-of-the-art AI models in days, enhancing the efficiency of data analysis for novel health insights.
- Amgen’s long-standing preparation for the integration of technology and biotechnology reflects a significant moment in the industry, as they combine their human data capabilities with NVIDIA’s advanced technologies.
The deployment of the NVIDIA DGX SuperPOD, Freyja, promises to transform drug discovery by harnessing the vast human data collected by Amgen over decades.
